BioSpace News Archive

Lantern Pharma Inc. (NASDAQ: LTRN), a clinical stage biopharmaceutical company using its proprietary RADR® artificial intelligence (“A.I.”) and machine learning (“M.L.”) platform to transform the cost, pace, and timeline of oncology drug discovery and development, today announced that the Company will present new preclinical data at three upcoming scientific conferences.

Aytu BioPharma, Inc. today announced an agreement with the Avenue Venture Opportunities Fund, L.P. (“Avenue Venture Debt Fund” or “Avenue”) to extend the interest-only period of the Company’s existing senior secured loan facility held with Avenue.

ENDRA Life Sciences Inc. (NASDAQ: NDRA), a pioneer of Thermo Acoustic Enhanced UltraSound (TAEUS®), announces that the United States Patent and Trademark Office has issued two new ENDRA patents, U.S. Patent No. 11456518 (the ‘518 patent) titled “Method for Manufacturing a Radio Frequency Applicator” and U.S. Patent No. 11478153 (the ‘153 patent) titled “System for Monitoring Tissue Temperature.”

Predictive Oncology (NASDAQ: POAI) is pleased to announce the appointment of David S. Smith, JD, to the company’s Board of Directors.

Veracyte, Inc . (Nasdaq: VCYT) announced new data demonstrating that a genomic signature derived from the company’s Decipher GRID database could help determine which men experiencing prostate cancer progression following radical prostatectomy (RP).

HeartBeam, Inc will hold a conference call on Thursday November 10, 2022 at 4:30 p.m. Eastern time to discuss its results for the third quarter ended September 30, 2022, and will be reviewing recent announcements, ongoing initiatives, and key 2022 and anticipated 2023 milestones.

Ginkgo Bioworks and the Ministry of Investment of Saudi Arabia today announced that they have entered into a non-binding Memorandum of Understanding with the intent of developing biotechnology and biosecurity capabilities to deploy new public health initiatives in the Kingdom of Saudi Arabia.

Evolus, Inc. today announced that it will report its third quarter 2022 financial results and provide a business update on Tuesday, November 8, 2022, after the U.S. financial markets close.

Biora Therapeutics, Inc today presented detailed results from its PM-602 study titled “A scintigraphic study to evaluate the localization and delivery function of a Drug Delivery System (DDS) device in patients with active ulcerative colitis (UC) in fasted state” during the American College of Gastroenterology (ACG) 2022 Annual Scientific Meeting.

NeuroOne Medical Technologies Corporation (Nasdaq: NMTC) (NeuroOne or the Company) today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) clearance to market its Evo sEEG Electrode technology for temporary (less than 30 days) use with recording, monitoring, and stimulation equipment for the recording, monitoring, and stimulation of electrical signals at the subsurface level of the brain.